Showing results (81-90 of 140) with videos related to
Sort By:
Pageof 14
Archives Des Maladies Du Coeur Et Des Vaisseaux|February 1, 1991
[Mitral valvuloplasty during the 4th month of pregnancy. Fetal protection with a lead mantle]G Drobinski, P Fraboulet, G Montalescot, et al.Arteriosclerosis, Thrombosis, and Vascular Biology|January 9, 2001
Disaggregation of in vitro preformed platelet-rich clots by abciximab increases fibrin exposure and promotes fibrinolysisJ P Collet, G Montalescot, C Lesty, et al.Journal of Applied Physiology (Bethesda, Md. : 1985)|October 1, 1989
Nafamstat mesilate attenuates pulmonary hypertension in heparin-protamine reactionsE Kreil, G Montalescot, E Greene, et al.Circulation|March 15, 2000
Low molecular weight heparin after mechanical heart valve replacementG Montalescot, V Polle, J P Collet, et al.Archives Des Maladies Du Coeur Et Des Vaisseaux|March 1, 1992
[Value of antimyosin monoclonal antibody scintigraphy in the diagnosis of acute myocardial infarction]P Amoyal, G Montalescot, D Ancri, et al.Clinical Cardiology|November 1, 1984
Lithium causing a serious sinus-node dysfunction at therapeutic dosesG Montalescot, Y Levy, D Farge, et al.The American Journal of Cardiology|March 15, 1996
Serial assessment of cardiopulmonary exercise capacity after cardiomyoplasty for either ischemic or idiopathic dilated cardiomyopathyA Cohen-Solal, R Choussat, J C Chachques, et al.International Journal of Cardiology|March 31, 2012
Comparison of various methods for quantitative evaluation of myocardial infarct volume from magnetic resonance delayed enhancement dataN Baron, N Kachenoura, P Cluzel, et al.Catheterization and Cardiovascular Diagnosis|February 1, 1993
Effects of ultrasound energy on thrombi in vitroF Philippe, G Drobinski, C Bucherer, et al.Therapeutic Drug Monitoring|December 16, 1998
Modeling INR data to predict maintenance fluindione dosageE Comets, F Mentré, F Pousset, et al.Pageof 14